Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fennec Pharmaceuticals Inc. on September 24, 2019. The company is incorporated in British Columbia, Canada, with principal executive offices in Research Triangle Park, NC. Its common shares trade on the Nasdaq Capital Market under the symbol "FENC".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary event reported is the appointment of Jodi A. Cook, PhD, to the Board of Directors effective September 24, 2019. There were no related party transactions or special understandings regarding her election.
Compensation and Equity Grant
- Annual Cash Compensation: $35,000, consistent with other directors.
- Equity Grant: 20,000 options to purchase common shares.
- Option Terms: Exercise price equal to Fair Market Value; 10-year term; 100% vested on the date of grant.
Outlook, Risks, and Contingencies
The filing does not provide management commentary on business outlook, risks, contingencies, or unusual items. It serves solely to disclose the director appointment and associated compensatory arrangements.
Key Facts for Investor Verification
- Verify the impact of the new board member on company strategy via the attached press release (Exhibit 99.1).
- Confirm the dilution impact of the 20,000 fully vested options granted to Dr. Cook.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.